Finance

Lists
1276:HKG
Jiangsu Hengrui Pharmaceuticals Co Ltd
47,60 HK$
-0,83%
(-0,40) 1D
16 қаз., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1276...
Open
48,00 HK$
High
49,30 HK$
Low
46,92 HK$
Mkt. cap
345,69 млрд
Avg. vol.
4,04 млн
Volume
4,16 млн
P/E ratio
34,86
52-wk high
84,50 HK$
52-wk low
43,02 HK$
EPS
1,37 HK$
No. of employees
21 мың
Open
48,00 HK$
High
49,30 HK$
Low
46,92 HK$
Mkt. cap
345,69 млрд
Avg. vol.
4,04 млн
Volume
4,16 млн
P/E ratio
34,86
52-wk high
84,50 HK$
52-wk low
43,02 HK$
EPS
1,37 HK$
No. of employees
21 мың
News stories
From web sources and news partners
Profile
Jiangsu Hengrui Pharmaceuticals Company Ltd., also known as Jiangsu Hengrui, is a Chinese pharmaceutical company that manufactures and distributes various types of drug packaging materials, cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics, and related products. It is the largest listed pharmaceutical company in China. Wikipedia
About Jiangsu Hengrui Pharmaceuticals Co Ltd
CEO-
Employees20,7 мың
Founded1970
Headquarters-
SectorPharmaceutical industry
Next call 8 күннен кейін
27 қаз., сс, 09:00
Fiscal period
Q3 2026
- / 0,31 CN¥
Revenue / Est. (CNY)
- / 9,17 млрд
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
7,43 млрд
8,44 млрд
8,14 млрд
7,32 млрд
Cost of goods sold
1,07 млрд
1,25 млрд
1,09 млрд
1,02 млрд
Cost of revenue
1,07 млрд
1,25 млрд
1,09 млрд
1,02 млрд
Research and development expenses
1,72 млрд
2,02 млрд
1,65 млрд
1,84 млрд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,23 млрд
3,01 млрд
2,81 млрд
2,78 млрд
Operating expense
4,76 млрд
5,35 млрд
4,48 млрд
4,61 млрд
Total operating expenses
5,83 млрд
6,60 млрд
5,57 млрд
5,63 млрд
Operating income
1,60 млрд
1,84 млрд
2,57 млрд
1,68 млрд
Other non operating income
-154,21 млн
145,74 млн
-345,12 млн
243,91 млн
EBT including unusual items
1,36 млрд
2,30 млрд
2,56 млрд
2,40 млрд
EBT excluding unusual items
1,68 млрд
1,91 млрд
2,55 млрд
1,60 млрд
Income tax expense
55,51 млн
338,85 млн
275,87 млн
211,27 млн
Effective tax rate
4,08%
14,76%
10,79%
8,82%
Other operating expenses
-217,30 млн
326,84 млн
4,76 млн
-5,09 млн
Net income
1,30 млрд
1,96 млрд
2,28 млрд
2,18 млрд
Net profit margin
17,52%
23,22%
28,04%
29,84%
Earnings per share
0,20
-
-
-
Interest and investment income
242,14 млн
288,66 млн
322,96 млн
448,28 м.
Interest expense
-689,68 м.
-2,00 млн
-448,28 м.
-322,96 млн
Net interest expenses
241,45 млн
286,66 млн
322,52 млн
-322,52 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,78 млрд
2,04 млрд
2,77 млрд
1,93 млрд
Gain or loss from assets sale
2,31 млн
-4,05 млн
-
-40,62 млн
AI content may include mistakes. Learn more
Google қолданбалары